What type of study is this?

This is a Prospective study (also classified as: Multicenter Cohort).

September 10, 2025Blood AdvancesOpen Access

Outcomes of Patients with Suspected Heparin-Induced Thrombocytopenia in a Contemporary Multicenter Cohort

View Full Paper

Ask AI

Bookmark

Authors

Prospective cohort analysis of treatment strategies for heparin-induced thrombocytopenia (HIT), revealing outcomes related to anticoagulants.

Treatment with argatroban reduced the risk of arterial thromboembolism in patients with confirmed HIT.
Among the cohort of 1,393 patients, 8.5% were diagnosed with HIT using the HIPA test as the reference standard.
Major bleeding occurred in 12.6% of patients, indicating a significant risk associated with heparin-induced thrombocytopenia treatment.
Outcomes were similar in HIT-negative patients regardless of the presence of heparin/PF4 antibodies.

Nilius et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Prospective cohort analysis of treatment strategies for heparin-induced thrombocytopenia (HIT), revealing outcomes related to anticoagulants.